Latest Content

Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma

December 10th 2024, 8:48pm

By Kristi Rosa

Article

Updated data from the phase 3 DREAMM-7 trial was presented during the 2024 ASH Annual Meeting and Exposition.

A Season of Setbacks and Thanks With Metastatic Breast Cancer

December 10th 2024, 6:00pm

By Martha Carlson

Article

Setbacks happen often in life, but finding gratitude can come at unexpected moments with cancer.

Uproleselan Fails to Improve Survival in AML, Although Some Subgroups May Benefit

December 10th 2024, 4:00pm

By Jordyn Sava

Article

A Phase 3 trial of uproleselan failed to improve overall survival in relapsed/refractory AML, though it may benefit primary refractory patients.

Venclexta Plus Mavenclad Boosts Response Rates in AML, MDS

December 10th 2024, 2:05pm

By Ariana Pelosci

Article

The Venclexta-based regimen improved complete response rates in patients with acute myeloid leukemia and myelodysplastic syndromes.

Heart Risk May Occur Less With Some BTK Inhibitors in B-Cell Blood Cancers

December 9th 2024, 11:00pm

By Ashley Chan

Article

In patients with certain B-cell blood cancers, heart-related side effects may occur less after receiving second-generation BTK inhibitors.

Brukinsa Supported as First-Line Treatment for Patients With CLL/SLL

December 9th 2024, 10:00pm

By Dylann Cohn-Emery

Article

Patients with treatment-naive CLL/SLL experienced long-term improved efficacy when treated with Brukinsa compared with bendamustine plus Rituxan.

Pelabresib Plus Jakafi Maintains Efficacy in JAK-Naive Myelofibrosis

December 9th 2024, 9:17pm

By Jonah Feldman

Article

Adding pelabresib to a JAK inhibitor may improve multiple aspects of myelofibrosis, including spleen size, symptoms and bone marrow fibrosis.

The Cancer Christmas Photo

December 9th 2024, 6:00pm

By Laura Yeager

Article

One year, after breast cancer treatment, I decided to have a Christmas photoshoot with my family, which turned out to be a good laugh in the end.

Tecvayli Effective Maintenance Therapy in Newly Diagnosed Multiple Myeloma

December 9th 2024, 5:00pm

By Jason Broderick

Article

Tecvayli alone or plus Revlimid has been found to be safe and may result in high MRD-negativity rates.

Darzalex Faspro May Improve Progression, Survival in Smoldering Multiple Myeloma

December 9th 2024, 3:00pm

By Kristie L. Kahl

Article

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with smoldering multiple myeloma.

Brain Cancer Survivor Reflects on Memoir and Her Journey

December 9th 2024, 2:00pm

By Spencer Feldman

Video

Maggie Bushway reflected on her memoir “Pearls: A Memoir on Childhood Cancer and Hope,” and her journey of healing and resilience after brain cancer.

Calquence Plus Venclexta Combo May Improve Survival in Frontline CLL

December 9th 2024, 12:50am

By Kristie L. Kahl

Article

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia.

Scemblix May Outperform Standard Treatments for Chronic Myeloid Leukemia

December 8th 2024, 11:47pm

By Megan Hollasch

Article

Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in patients with chronic myeloid leukemia.

Navtemadlin Shows Biomarker Response in Patients with R/R Myelofibrosis

December 8th 2024, 11:25pm

By Morgan Bayer

Article

Patients with relapsed or refractory (R/R) myelofibrosis experienced reduced biomarkers of disease severity following treatment with navtemadlin.

Tecartus Shows Similar Efficacy Across Age Groups in Leukemia

December 8th 2024, 11:00pm

By Kyle Doherty

Article

Tecartus demonstrated similar effectiveness across age groups of patients with relapsed or refractory B-cell acute lymphoblastic leukemia.